Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

rheumatoid arthritis

This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Fostamatinib was being developed as a treatment for rheumatoid arthritis by AstraZeneca (AZ), but the big pharma company returned rights to the drug in 2013 after disappointing phase III trials.

Latest news

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    AbbVie’ s upadacitinib aces phase III trial. Arthritis drug outperformed both placebo and Humira in the study. ... AbbVie’s JAK1 inhibitor upadacitinib has proved more effective than the company’s widely-used TNF blocker Humira in a phase III trial

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    Sandoz’Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Eli Lilly has decided to abandon trials of its BTK inhibitor HM71224 in rheumatoid arthritis after an interim look at its prospects. ... rheumatoid arthritis in Europe and after a delay has refiled the drug in the US, he said.

  • AbbVie reports more solid data for would-be psoriasis blockbuster AbbVie reports more solid data for would-be psoriasis blockbuster

    New drugs are starting to chip away at the dominance of AbbVie’s anti-TNF drug Humira (adalimumab) in psoriasis and other indications like rheumatoid arthritis, although it still dwarfs them ... Upadacitinib is vying to become the third drug in the

  • Arthritis patient group launches interactive video initiative Arthritis patient group launches interactive video initiative

    Arthritis patient group launches interactive video initiative. NRAS hopes its Love Your Heart programme will lower CV risks in those with RA. ... A UK arthritis patient group has launched an interactive video programme that it hopes will help lower

More from news
Approximately 59 fully matching, plus 414 partially matching documents found.

Latest Intelligence

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

  • Mobile health and patient outcomes Mobile health and patient outcomes

    In a recent study in rheumatoid arthritis, patients saw pain as the key measure of treatment success, confounding the objective ‘clinical evidence’of improvement.

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    Pain has nervous and inflammatory components and we are interested in everything around the inflammatory process but also the central nervous system aspect of pain and adjunctive diseases such as rheumatoid ... arthritis and Parkinson’s.

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small

More from intelligence
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Infographic: RA market snapshot

    Infographic: RA market snapshot. An overview of the RA biologic patient. Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses are based on 139, 984

  • Living with RA Report

    Living with RA Report. Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

  • Research Partnership publishes 2016 Living with RA reports

    Research Partnership publishes 2016 Living with RA reports. Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016. ... Living with RA is a quantitative study conducted online amongst 500 patients

  • Infographic: RA Perceptions

    adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time.

  • THE OTHER SIDE OF … RHEUMATOID ARTHRITIS

    THE OTHER SIDE OF … RHEUMATOID ARTHRITIS. “ I harassed my GP enough to get it caught early”. ... Meet Georgie. At age 26, Georgie was diagnosed with rheumatoid arthritis, an autoimmune inflammatory condition that affects up to 1% of the population

More from PMHub
Approximately 6 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia